The immense value of this method for breast cancer treatment was impressively underlined by the studies of scientists Professor Dr. Nadia Harbeck and Professor Dr. Ulrike Nitz (West German Study Group) and has now been awarded the German Cancer Prize 2023 in the Clinical Cancer Research category. Multigene tests allow breast cancer treatments to be tailored precisely to the individual needs of patients. Particularly in the case of hormone-sensitive breast cancer, such tests help to predict whether patients can benefit from chemotherapy in addition to anti-hormone therapy. The decision in favor of chemotherapy-free treatment with less stress becomes possible without reducing the chances of recovery.
Dr. Martin Walger, Managing Director of the Association of the Diagnostics Industry (VDGH), says: "The impressive results of these studies should help to increase the use of such tests in everyday clinical practice. Patients benefit enormously from personalized medicine and the crucial role of companion diagnostics. The ongoing development of companion diagnostics not only supports progress in the treatment of breast cancer, but also has the potential to fundamentally change the treatment of diseases."
The VDGH believes that diagnostics will play an increasingly important key role in modern medicine. The added value and benefits of diagnostics go far beyond the cost discussion and focus on improving patient care and maximizing therapy efficiency.
Despite the enormous opportunities offered by companion diagnostics, the reality in healthcare still shows a considerable discrepancy between potential and actual application: In 2021, only around 10 percent of women suffering from hormone-sensitive breast cancer were supported in their treatment decision by a multigene test.
